Side-effects of cidofovir in the treatment of recurrent respiratory papillomatosis

Autor: Ferdinand I. Broekema, Frederik G. Dikkers
Rok vydání: 2008
Předmět:
Male
PROTOCOL
Larynx
animal diseases
viruses
CHILDREN
Review Article
Injections
Intralesional
THERAPY
chemistry.chemical_compound
Child
HUMAN PAPILLOMAVIRUS-11 DNA
larynx
JUVENILE LARYNGEAL PAPILLOMATOSIS
Incidence (epidemiology)
virus diseases
INTRAVENOUS CIDOFOVIR
General Medicine
respiratory system
papilloma
medicine.anatomical_structure
INTRALESIONAL CIDOFOVIR
Female
SQUAMOUS-CELL CARCINOMA
Neurosurgery
Cidofovir
Adult
medicine.medical_specialty
Adolescent
Organophosphonates
Antineoplastic Agents
cidofovir
Cytosine
medicine
Animals
Humans
Laryngeal Neoplasms
business.industry
biochemical phenomena
metabolism
and nutrition
medicine.disease
Dermatology
Surgery
Otorhinolaryngology
chemistry
Dysplasia
side-effects
Papilloma
Neoplasm Recurrence
Local
INJECTION
Recurrent Respiratory Papillomatosis
FOLLOW-UP
business
recurrent respiratory papillomatosis
Zdroj: European Archives of Oto-Rhino-Laryngology
ISSN: 1434-4726
0937-4477
DOI: 10.1007/s00405-008-0658-0
Popis: Recurrent respiratory papillomatosis (RRP) is a chronic and difficult to treat disease of the larynx. In 1998, the first article was published that described the use of the antiviral substance cidofovir to treat this disease. Although the results are promising, there remains some concern about the potential carcinogenicity of cidofovir. There is a demand for a qualitative review of the side-effects of this medicine. In this review, the side-effects of cidofovir are investigated. Special attention was given to the potential carcinogenicity of cidofovir. For this review a search is performed in PubMed and EMBASE for relevant articles in which the use of intralesional cidofovir for patients with RRP is described. Eventually, 31 articles could be included for this review. In these articles a total of 188 patients with RRP were described who underwent therapy with intralesional cidofovir. Five of these patients have developed dysplasia of the larynx during the treatment with cidofovir. This is a percentage of 2.7. This percentage is concurrent with the incidence of spontaneous malignant degeneration of RRP (2–3%). Based on this review, it can be concluded that the use of intralesional cidofovir does not increase the risk of laryngeal dysplasia. Apart from the articles that describe the intralesional administration of cidofovir, some articles have been published in which the use of intravenous cidofovir is described as a therapy for RRP. Therefore, a summary is given on the side-effects of intralesional cidofovir as well as a summary on the reported side-effects of the intravenous administration of cidofovir. Based on the outcomes of this review, recommendations are given for a safe use of cidofovir for treatment of recurrent respiratory papillomatosis in the future.
Databáze: OpenAIRE
Externí odkaz: